Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 18.63 as of 2026-09-25T00:16:02.235Z.
Consensus retrieved: 2026-09-13T23:53:50.524Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-25T00:16:02.235Z.
Quote observation: 2026-09-24T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4f4ede9639e9c96fbf57e3bd490e7fbd6a5b098d94fb763da7d8d88c736b0e56
Forward PE Ratio (18.63) = Dated Quote Price ($208.77) / Consensus Forward EPS ($11.21)
FORWARD PE RATIO
18.63
SECTOR MEDIAN · HEALTHCARE
18.75
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
-0.64%
vs the sector median at left
STERIS plc
Market Cap
$20.35B
Forward PE Ratio
18.63
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| STERIS plc (STE) | $20.35B | 18.63 |
| Viatris Inc. (VTRS)vs › | $20.29B | 6.97 |
| United Therapeutics Corporation (UTHR)vs › | $20.04B | 18.06 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.35B | 10.51 |
| Medpace Holdings, Inc. (MEDP)vs › | $17.32B | 35.26 |
| Revvity, Inc. (RVTY)vs › | $16.81B | 28.14 |
| BioNTech SE (BNTX)vs › | $24.93B | N/A |
| Incyte Corporation (INCY)vs › | $25.22B | 33.08 |
| Labcorp Holdings Inc. (LH)vs › | $25.33B | 16.84 |
| Solventum Corporation (SOLV)vs › | $15.34B | 12.37 |
Trailing P/E
25.5
reported TTM EPS
Forward P/E
18.6
consensus EPS · fiscal year ending 2027-03-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $11.21 implies +37.0% EPS growth vs the reported trailing $8.18.
At the dated quote price of $208.77, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-03-31 | $11.21 | $11.01 – $11.32 | 6 | 18.6x |
| 2028-03-31 | $12.25 | $12.22 – $12.27 | 6 | 17.0x |
| 2029-03-31 | $13.47 | $12.49 – $15.42 | 4 | 15.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
